Pfizer's revenue has halved from its pandemic peak, but the oncology pipeline — anchored by a $43 billion Seagen acquisition — is the most ambitious portfolio rebuild in pharma history.
Pfizer finds itself in a position no pharmaceutical company wants to be in: staring down a revenue cliff with the clock ticking. The COVID vaccine and Paxlovid franchise, which generated over $56 billion at peak, has deflated to a fraction of that. Trailing revenue sits at $49.3 billion, down from $100.3 billion in 2022.
But here's what the doom-and-gloom narrative misses: Pfizer has used the COVID windfall to execute the most aggressive pipeline acquisition strategy in pharma history, headlined by the $43 billion purchase of Seagen. The question for investors isn't whether Pfizer's revenue will decline further — it probably will in 2026. It's whether the oncology portfolio can inflect fast enough to create a new growth platform by 2027-2028.
To understand where Pfizer is going, you have to reckon with where it's been. The company generated $100.3 billion in 2022 revenue — a figure so extraordinary it distorted every financial metric. Revenue per employee, R&D as a percentage of sales, operating margins — all became temporarily meaningless.
The hangover has been brutal. Revenue dropped to $58.5 billion in 2023, then $49.3 billion in 2024, and consensus expects $48-50 billion for 2025. COVID products now contribute roughly $5-7 billion annually, down from $56 billion at peak. This isn't a business in decline — it's a business returning to its pre-pandemic trajectory after a one-time windfall.
The market, however, is pricing Pfizer as though the revenue decline is structural rather than compositional. That's where we see the disconnect.
TickerXray Report
Get the complete Pfizer report with all 12 quantitative models, AI-generated investment thesis, and real-time data.
Pfizer's $43 billion acquisition of Seagen in late 2023 was the largest pharma deal in years, and it divided the analyst community. Bulls saw a visionary pivot into the highest-growth segment of pharma. Bears saw a desperate company overpaying for assets to fill a revenue hole.
Eighteen months in, the early evidence favours the bulls. Seagen's antibody-drug conjugate (ADC) portfolio — led by Padcev and Adcetris — generated $3.4 billion in 2025 revenue, up 45% year-over-year. Padcev in particular has emerged as a potential blockbuster in bladder cancer, with label expansion trials showing strong results across additional tumour types.
The Research Desk has covered enough pharma acquisitions to know the pattern: the first 18 months are about integration costs and revenue dis-synergies. The real value creation happens in years 2-4, when the combined pipeline begins producing approvals from assets that neither company could have advanced alone. Pfizer is entering that phase now.
Beyond Seagen, Pfizer's internal oncology pipeline includes 12 compounds in Phase 2 or later, targeting breast cancer, lung cancer, and haematological malignancies. Management has guided for 8 potential blockbuster launches by 2028. Even if half of those hit, they represent $15-20 billion in incremental revenue.
Here's what makes Pfizer interesting from a pure numbers perspective. The stock trades at roughly 9x forward earnings — a multiple typically reserved for companies with no growth, deteriorating margins, or balance sheet distress. Pfizer has none of these.
Profit margins have recovered to 18% from the post-Seagen integration trough, and consensus expects expansion to 22% by 2027 as integration costs fade and higher-margin oncology products scale. The balance sheet carries $62 billion in debt — heavy, but manageable at 3.2x EBITDA with $9.9 billion in operating cash flow.
The dividend yields 6.2% at current prices and is covered 1.4x by free cash flow. Management has explicitly committed to maintaining the dividend through the transition. For a company with this cash flow profile and a visible growth catalyst, a sub-10x multiple is, frankly, staggering.
Analyst consensus has a target of $30.41 with 7 buys, 9 holds, and 2 sells. The spread between the most bullish ($42) and most bearish ($22) target reflects genuine uncertainty about the pipeline. We think the optimists have the better argument.
Pfizer's oncology pivot places it in direct competition with Merck (Keytruda franchise), Bristol-Myers Squibb (checkpoint inhibitors), and AstraZeneca (ADCs via Enhertu). Each has strengths, but Pfizer's breadth of modalities — spanning ADCs, bispecifics, small molecules, and mRNA-based cancer vaccines — gives it optionality that the others lack.
The mRNA cancer vaccine programme, leveraging the COVID vaccine platform, is particularly underappreciated. Phase 2 data in melanoma showed a 44% reduction in recurrence when combined with Keytruda. If the Phase 3 confirms this, Pfizer has a potential $5 billion product that the market is assigning essentially zero value to.
Amazon's advertising business followed a similar trajectory to what we're seeing with Pfizer's oncology pivot — quietly becoming the profit engine while the market obsessed over a different part of the business entirely.
The risks are real. Pipeline failure is the obvious one — if Padcev's label expansion studies disappoint or the mRNA cancer vaccine Phase 3 misses, the growth narrative collapses. Patent cliffs on legacy products (Eliquis loses exclusivity in 2026) will pressure base revenue.
The debt load, while manageable, limits flexibility. If the oncology transition takes longer than expected, Pfizer may face a choice between the dividend and the pipeline — and that's a decision no pharma CEO wants to make.
But the risk-reward at 9x earnings already prices in a substantial probability of failure. The market is essentially saying: the pipeline probably won't work. We think the data so far says otherwise.
Pfizer at 9x forward earnings with a 6.2% dividend yield, a $43 billion oncology acquisition showing early commercial traction, and a mRNA cancer vaccine platform the market assigns no value to — that's a compelling setup by any measure.
The next 12-18 months will be messy. Revenue may dip further before the oncology portfolio scales. But for investors willing to look through the trough, we think Pfizer offers 40-60% upside to a fair value of $35-40 by 2028.
We're buyers at current levels, and we'd be adding on any move below $24. The oncology pivot is working. The market just hasn't noticed yet.
Full forensic analysis of Pfizer
+ 6 more models included
150,000+ stocks covered
Global coverage across 60+ exchanges. Every report includes all 12 quantitative models and AI analysis.
View plansEvery report runs 12 quantitative models and generates an AI investment thesis. From Piotroski scores to manipulation detection -- get the full picture in seconds.
12 forensic models
Piotroski, Altman, Beneish, DuPont & more
AI investment thesis
Synthesized outlook on every stock
Manipulation detection
Spot red flags before they hit the news
150,000+ tickers
Global coverage across 60+ exchanges
Expected return
Forward return projections for every stock
Real-time data
Live prices, insider trades, news sentiment
Free accounts get 1 report per month. Pro gets unlimited.
The licensing deal announced this week with Arvinas via Rigel adds an estrogen receptor degrader to the breast cancer pipeline. The bigger picture: Pfizer is paying for pipeline replacement at a moment when the patent cliff is six quarters away.
Pfizer trades at 8.7x forward earnings and a 6.6% dividend yield. The market is telling you something. Here are five reasons it is not a screaming buy.
Pfizer trades at 9.4x forward earnings with $9 billion of free cash flow and a 7% dividend yield. The consensus has priced a patent cliff apocalypse that the pipeline numbers do not actually support.